Table of contents

Original Articles

• Gynecological tumors revealing hereditary nonpolyposis colorectal cancer: analysis of a large Lebanese pedigree (1 July, 2006)

  R. Akoum, A. Ghaoui, E. Brihi, M. Ghabash, J Abou Atme
• Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study (1 July, 2006)

  C. Marth, G. H. Windbichler, H. Hausmaninger, E. Petru, K. Estermann, A. Pelzer, E. Mueller-Holzner
• High expression of insulin-like growth factor binding protein–2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels (1 July, 2006)

  J. M. Lancaster, R. A. Sayer, C. Blanchette, B. Calingaert, I. Konidari, J. Gray, J. Schildkraut, D. W. Schomberg, J. R. Marks, A. Berchuck
• Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property (1 July, 2006)

  N. Jandu, M. Richardson, G. Singh, H. Hirte, M. W.C Hatton
• Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis (1 July, 2006)

  T. Yagyu, Y. Tsuji, S. Haruta, T. Kitanaka, Y. Yamada, R. Kawaguchi, S. Kanayama, Y. Tanase, N. Kurita, H. Kobayashi
• Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity (1 July, 2006)

  N. Askar, T. Cirpan, E. Toprak, B. Karabulut, N. Selvi, M. C. Terek, R. Uslu, U. A. Sanli, E. Goker
• Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma (1 July, 2006)

  K. Staflin, S. Järnum, J. Hua, G. Honeth, P. Kannisto, M. Lindvall
• Women in a region with high incidence of cervical cancer warrant immediate colposcopy for low-grade squamous intraepithelial lesion on cervical cytology (1 July, 2006)

  C. Phongnarisorn, J. Srisomboon, S. Siriaungkul, S. Khunamornpong, P. Suprasert, K. Charoenkwan, C. Cheewakriangkrai, S. Siriaree, K. Saphan
• What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case–control study (1 July, 2006)

  K. BM. Lee, J. M. Lee, C. Y. Park, K. B. Lee, H. Y. Cho, S. Y. Ha
• Loop conization for the treatment of microinvasive carcinoma of the cervix (1 July, 2006)

  C. J. Tseng, C. C. Chang, C. C. Tseng, H. C. Hou, C. B. Wang, C. H. Chen, Y. K. Soong, C. C. Pao
• A comparative study of two devices used for cervical cell sampling raises some doubts about liquid-based cytology (1 July, 2006)

  A. Kothari, S. Z. Karim, A. Gordon, F. Raslan, M. Abdalla, S. George
• Urine cytology as a screening test for bladder infiltration in cervical cancer (1 July, 2006)

  L. C. Snyman, B. A. Zondagh, G. Dreyer, B. G. Lindeque, M. Louw
• Human papillomavirus genotypes associated with cervical neoplasia in India (1 July, 2006)

  A. Peedicayil, P. Abraham, N. Sathish, S. John, K. Shah, G. Sridharan, P. Gravitt
• Candida and squamous (pre)neoplasia of immigrants and Dutch women as established in population‐based cervical screening

  (1 July, 2006)

  M. K. Engberts, C. F.W Vermeulen, B. S.M Verbruggen, M. Van Haaften, M. E. Boon, A. P.M Heintz
• Detection of human papillomavirus in organs of upper genital tract in women with cervical cancer (1 July, 2006)

  G. Giordano, T. D'adda, L. Gnetti, E. Froio, C. Merisio, M. Melpignano
• Risk factors for the progression or persistence of untreated mild dysplasia of the uterine cervix (1 July, 2006)

  S. H. Song, J. K. Lee, M. J. Oh, J. Y. Hur, Y. K. Park, H. S. Saw
• A phase I study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy (1 July, 2006)

  C. Nyongesa, P. Ruff, B. Donde, J. Kotzen
• Enhanced radiation-mediated cell killing of human cervical cancer cells by small interference RNA silencing of ataxia telangiectasia-mutated protein (1 July, 2006)

  W. Li, W. Jian, X. Xiaoping, L. Yingfeng, X. Tao, X. Xiaoyan
• Upregulation of CD44 expression by interleukins 1, 4, and 13, transforming growth factor-β1, estrogen, and progestogen in human cervical adenocarcinoma cell lines (1 July, 2006)

  E. M. Ibrahim, R. L. Stewart, K. Corke, A. D. Blackett, J. A. Tidy, M. Wells
• Reverse transcription–polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers (1 July, 2006)

  Z. Lin, Y. Nan, X. Zhang, Y. Zhao, C. Kim, I. Kim
• Stage III and IV endometrial cancer: a 20-year review of patients (1 July, 2006)

  F. H. Van Wijk, F. J. Huikeshoven, L. Abdulkadir, P. C. Ewing, C. W. Burger
• Function of estrogen receptor isoforms α and β in endometrial carcinoma cells (1 July, 2006)

  Y. Zhang, Q. Liao, C. Chen, L. Yu, J. Zhao
• Mitochondrial polymorphisms as risk factors for endometrial cancer in southwest China (1 July, 2006)

  L. Xu, Y. Hu, B. Chen, W. Tang, X. Han, H. Yu, C. Xiao
• Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma (1 July, 2006)

  W. Wu, B. M. Slomovitz, P. T. Soliman, K. M. Schmeler, J. Celestino, M. R. Milam, K. H. Lu
• Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma (1 July, 2006)

  W. Li, R. J. Xu, H. H. Zhang, L. H. Jiang
• Expression of matrix metalloproteinase-2 and mutant p53 is increased in hydatidiform mole as compared with normal placenta (1 July, 2006)

  P. Petignat, R. Laurini, F. Goffin, I. Bruchim, P. Bischof